Tag Archives: Alan Carr

Needham Remains a Buy on Cara Therapeutics (CARA)

In a report released today, Alan Carr from Needham maintained a Buy rating on Cara Therapeutics (CARA – Research Report), with a price target of $35.00. The company’s shares closed last Monday at $19.34. According to TipRanks.com, Carr is a

Lexicon Pharmaceuticals (LXRX) Gets a Hold Rating from Needham

Needham analyst Alan Carr maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed last Monday at $1.72, close to its 52-week low of $1.13. According to TipRanks.com, Carr is a 3-star analyst with

Needham Reiterates Their Hold Rating on Regulus (RGLS)

Needham analyst Alan Carr reiterated a Hold rating on Regulus (RGLS – Research Report) yesterday. The company’s shares closed last Monday at $0.58, close to its 52-week low of $0.50. According to TipRanks.com, Carr is a 3-star analyst with an

Needham Thinks Moderna Inc’s Stock is Going to Recover

In a report issued on August 7, Alan Carr from Needham maintained a Buy rating on Moderna Inc (MRNA – Research Report), with a price target of $28. The company’s shares closed on Friday at $13.33, close to its 52-week

Needham Keeps Their Buy Rating on SCYNEXIS (SCYX)

In a report issued on August 8, Alan Carr from Needham maintained a Buy rating on SCYNEXIS (SCYX – Research Report), with a price target of $5. The company’s shares closed on Friday at $1. According to TipRanks.com, Carr is

Needham Reaffirms Their Hold Rating on Tetraphase (TTPH)

Needham analyst Alan Carr maintained a Hold rating on Tetraphase (TTPH – Research Report) on August 9. The company’s shares closed on Friday at $0.31, close to its 52-week low of $0.31. According to TipRanks.com, Carr is a 3-star analyst